+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TARA-002 for treating high-grade non-muscle invasive bladder cancer NMIBC in adults 18 years and older who have not previously received BCG treatment. This Phase 3 randomized study aims to compare TARA-002 with chemotherapy chosen by investigators to see if TARA-002 can help participants with this type of bladder cancer and to understand its side effects. Participants will receive either six weekly doses of TARA-002 or six weekly doses of intravesical chemotherapy. Those who achieve a complete response at Week 12 will enter a maintenance phase. For TARA-002, maintenance involves three weekly doses every three months up to Month 19, then three weekly doses at Month 25. Participants eligible for reinduction at Week 12 may receive six additional weekly doses, followed by the same maintenance schedule if they respond at Week 24. For chemotherapy, maintenance involves one dose every month up to Month 25. During the study, participants will undergo assessments to measure the incidence of complete response at six months and other outcomes up to five years, including duration of response, recurrence, progression, survival, and safety events. Regular monitoring will include evaluating side effects and long-term outcomes such as time to surgery and disease worsening. The total participation may last up to 60 months to fully assess these outcomes.

Age: 18Years +All GendersPhase 3
11 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TARA-002, a biological preparation containing cells of Streptococcus pyogenes, in adults 18 years and older with high-grade non-muscle invasive bladder cancer NMIBC including carcinoma in situ CIS with or without TaT1. This Phase 2 open-label study aims to further assess TARA-002 at the recommended Phase 2 dose established in a prior dose-finding study. Participants include those who are BCG naive, BCG exposed but not recently treated, or BCG unresponsive. Participants will receive intravesical instillations of TARA-002 in a structured treatment schedule. The first period consists of 6 weekly doses. Those eligible for reinduction will receive another 6 weekly doses, while participants with a complete response after the first period will get 3 weekly maintenance doses. A third treatment period includes 3 weekly maintenance doses administered at months 6, 9, 12, 15, 18, and 24. Following treatment, participants enter a follow-up period lasting from month 27 to month 60. Throughout the study, participants will be monitored for tumor response, including high-grade complete response rates and duration, progression-free survival, cystectomy timing, and survival outcomes up to 60 months. Safety assessments include monitoring adverse events and biomarker changes in urine. Quality of life questionnaires will be administered up to 24 months. This comprehensive evaluation aims to understand TARA-002s effects and safety over time in this patient population.

Age: 18Years +All GendersPhase 2
78 locations